Detalles de la búsqueda
1.
Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC.
N Engl J Med
; 389(21): 1935-1948, 2023 Nov 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-37937763
2.
ASPiRATION: Australian observational cohort study of comprehensive genomic profiling in metastatic lung cancer tissue.
Future Oncol
; 20(7): 361-371, 2024 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-37767626
3.
Limited clinical activity of palbociclib and ribociclib monotherapy in advanced cancers with cyclin D-CDK4/6 pathway alterations in the Dutch DRUP and Australian MoST trials.
Int J Cancer
; 153(7): 1413-1422, 2023 10 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37424386
4.
Pre- and on-treatment lactate dehydrogenase as a prognostic and predictive biomarker in advanced non-small cell lung cancer.
Cancer
; 128(8): 1574-1583, 2022 04 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-35090047
5.
Efficacy and safety of olaparib according to age in BRCA1/2-mutated patients with recurrent platinum-sensitive ovarian cancer: Analysis of the phase III SOLO2/ENGOT-Ov21 study.
Gynecol Oncol
; 165(1): 40-48, 2022 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-35115180
6.
Cardiac assessment in Australian patients receiving (neo)adjuvant trastuzumab for HER2-positive early breast cancer: a population-based study.
Breast Cancer Res Treat
; 187(3): 893-902, 2021 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-33616773
7.
Correction: Treatment patterns and survival in HER2-positive early breast cancer: a whole-of-population Australian cohort study (2007-2016).
Br J Cancer
; 123(5): 868, 2020 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-32472094
8.
Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer.
N Engl J Med
; 376(7): 629-640, 2017 02 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-27959700
9.
Treatment patterns and survival in HER2-positive early breast cancer: a whole-of-population Australian cohort study (2007-2016).
Br J Cancer
; 121(11): 904-911, 2019 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-31673103
10.
Predictive value of PD-L1 and other clinical factors for chemoimmunotherapy in advanced non-small-cell lung cancer.
Future Oncol
; 15(20): 2371-2383, 2019 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-31354046
11.
Cancer Molecular Screening and Therapeutics (MoST): a framework for multiple, parallel signal-seeking studies of targeted therapies for rare and neglected cancers.
Med J Aust
; 209(8): 354-355, 2018 10 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-30138578
12.
Poor Concordance Between Cancer Antigen-125 and RECIST Assessment for Progression in Patients With Platinum-Sensitive Relapsed Ovarian Cancer on Maintenance Therapy With a Poly(ADP-ribose) Polymerase Inhibitor.
J Clin Oncol
; 42(11): 1301-1310, 2024 Apr 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-38215359
13.
'A most malignant malady': a rare case of laryngeal tuberculosis in epidermal growth factor receptor mutant lung adenocarcinoma.
Intern Med J
; 47(10): 1215-1216, 2017 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-28994257
14.
Generalizability of immune checkpoint inhibitor trials to real-world patients with advanced non-small cell lung cancer.
Lung Cancer
; 166: 40-48, 2022 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-35152172
15.
VEGF-A, VEGFR1 and VEGFR2 single nucleotide polymorphisms and outcomes from the AGITG MAX trial of capecitabine, bevacizumab and mitomycin C in metastatic colorectal cancer.
Sci Rep
; 12(1): 1238, 2022 01 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-35075138
16.
Plasma pre-treatment T790M relative allelic frequency in patients with advanced EGFR-mutated non-small cell lung cancer predicts treatment response to subsequent-line osimertinib.
Transl Lung Cancer Res
; 10(4): 1623-1634, 2021 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-34012779
17.
Prognostic nomogram for progression-free survival in patients with BRCA mutations and platinum-sensitive recurrent ovarian cancer on maintenance olaparib therapy following response to chemotherapy.
Eur J Cancer
; 154: 190-200, 2021 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-34293664
18.
Concordance between CA-125 and RECIST progression in patients with germline BRCA-mutated platinum-sensitive relapsed ovarian cancer treated in the SOLO2 trial with olaparib as maintenance therapy after response to chemotherapy.
Eur J Cancer
; 139: 59-67, 2020 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-32977221
19.
Evaluation of Phase II Trial Design in Advanced Pancreatic Cancer.
Pancreas
; 48(10): 1274-1284, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-31688590
20.
Performance of four published risk models to predict sentinel lymph-node involvement in Australian women with early breast cancer.
Breast
; 41: 82-88, 2018 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-30007272